| Literature DB >> 35592398 |
Bruno Evrard1,2, Bálint Károly Lakatos3, Marine Goudelin1,2, Zoltán Tősér4, Béla Merkely3, Philippe Vignon1,2, Attila Kovács3.
Abstract
Aim: To compare global and axial right ventricular ejection fraction in ventilated patients for moderate-to-severe acute respiratory distress syndrome (ARDS) secondary to early SARS-CoV-2 pneumonia or to other causes, and in ventilated patients without ARDS used as reference.Entities:
Keywords: 3D echocardiography (3DE); COVID-19; acute respiratory distress syndrome—ARDS; myocardial deformation; right ventricle (RV)
Year: 2022 PMID: 35592398 PMCID: PMC9110691 DOI: 10.3389/fcvm.2022.861464
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
FIGURE 1Study flow chart.
Characteristics of the study population.
| ARDS related to SARS-CoV-2 (Group 1) | ARDS unrelated to SARS-CoV-2 (Group 2) | Controls (Group 3) | Paired | ||
| Age (years) | 69(56−74)† | 62(50−71) | 51(32−59)† | 0.006 | 0.89 |
| Sex (Male) | 15(71%) | 19(86%) | 14(67%) | 0.3 | − |
| Body Mass Index (kg/cm2) | 29.0(26.0−33.0) | 26.7(24.5−31.6) | 27.9(27.3−33.4) | 0.2 | − |
| Comorbidity | |||||
|
| 1(5%) | 1(5%) | 0(0%) | 0.6 | − |
|
| 12(57%) | 8(36%) | 4(19%) | 0.038 | − |
|
| 7(33%) | 1(5%) | 1(5%) | 0.008 | − |
|
| 10(48%) | 7(32%) | 6(29%) | 0.4 | − |
|
| 0(0%) | 1(5%) | 1(5%) | 0.6 | − |
| Norepinephrine | 3(14%) | 14(64%) | 0(0%) | < 0.001 | <0.001 |
| Alive at discharge | 15(71%) | 17(77%) | 15(71%) | 0.9 | − |
| SAPSII | 34(28−40) | 42(32−56)* | 31(24−39)* | 0.022 | 0.132 |
| SOFA | 4(3−4) | 6(4−7)* | 3(2−4)* | 0.006 | 0.039 |
| Cause of ARDS | |||||
|
| − | 10(45%) | |||
|
| − | 3(13%) | − | − | − |
|
| − | 4(18%) | − | − | − |
|
| − | 2(9%) | − | − | − |
|
| − | 3(13%) | − | − | − |
Hemodynamic and ventilatory parameters at the time of echocardiography assessment.
| ARDS related to SARS-CoV-2 (Group 1) | ARDS unrelated to SARS-CoV-2 (Group 2) | Controls (Group 3) | Paired | ||
| Heart rate (bpm) | 92(85−113) | 94(84−108) | 101(88−114) | 0.7 | − |
| Systolic arterial pressure (mmHg) | 140(120−152) | 124(116−128)* | 141(133−160)* | 0.012 | 0.087 |
| Mean arterial pressure (mmHg) | 95(84−103) | 86(79−90)* | 96(91−105)* | 0.018 | 0.092 |
| Tidal volume (mL/kg) | 6.88(6.53−7.23) | 6.51(5.91−7.06) | 7.08(6.69−7.71) | 0.095 | − |
| PEEP (cm/H2O) | 10.00(10.00−12.00)† | 10.50(9.25−12.00)* | 8.00(7.00−8.00)*† | 0.001 | 1.00 |
| Plateau pressure (cmH2O) | 25.0(22.0−26.0)† | 25.5(24.0−27.8)* | 15.5(15.0−16.5)*† | <0.001 | 0.52 |
| Driving pressure (cmH2O) | 13.0(11.0−16.0)† | 14.5(13.0−16.8)* | 8.0(7.5−9.5)*† | <0.001 | 0.24 |
| Static compliance (mL/cmH2O) | 34(30−42)† | 32(27−36)* | 49(44−66)*† | 0.002 | 0.65 |
| PaO2/FiO2 | 118(77−185)† | 154(100−181)* | 286(253−373)*† | <0.001 | 1.00 |
| PaCO2 (mmHg) | 44(36−52) | 49(42−61)* | 35(32−40)* | 0.002 | 0.34 |
| Ventilatory ratio | 1.95(1.63−2.15) | 2.09(1.77−2.50) | − | − | 0.822 |
Two-dimensional echocardiography parameters.
| ARDS related to SARS-CoV-2 (Group 1) | ARDS unrelated to SARS-CoV-2 (Group 2) | Controls (Group 3) | Paired | ||
| Indexed LV end-diastolic volume (mL/m2) | 44.0(38.5−48.7)− | 43.2(36.1−47.7) | 38.2(25.8−49.2) | 0.63 | − |
| Indexed LV end-systolic volume (mL/m2) | 20.6(18.8−27.2) | 20.0(12.5−23.5) | 13.3(9.9−15.9) | 0.087 | − |
| LV ejection fraction (%) | 52.0(47.6−62.4) | 54.5(46.0−65.8) | 62.7(58.1−67.6) | 0.016 | 0.91 |
| LV outflow tract VTI (cm) | 21.0(18.0−23.3) | 18.0(16.2−20.5) | 21.7(17.0−25.9) | 0.2 | − |
| Cardiac index (l/min/m2) | 2.7(2.5−3.3) | 2.7(2.5−3.4) | 3.1(2.9−3.9) | 0.3 | − |
| RV/LV end-diastolic area | 0.55(0.53−0.69) | 0.68(0.53−0.72)* | 0.54(0.46−0.58)* | 0.044 | 0.44 |
| RV fractional area change (%) | 45(33−50) | 28(25−35)* | 42(34−50)* | <0.001 | 0.003 |
| TAPSE (mm) | 24.0(21.5−27.0) | 19.3(15.2−20.7)* | 26.0(21.8−27.2)* | 0.005 | 0.025 |
| Tricuspid annular S’ wave (cm/s) | 16.0(14.3−18.1) | 15.0(12.0−17.8) | 18.3(15.7−22.0) | 0.067 | − |
| Vmax tricuspid regurgitation (cm/s) | 3.05(2.65−3.48) | 2.90(2.80−2.92) | 2.70(2.30−2.88) | 0.3 | − |
| Right atrio-ventricular systolic pressure gradient (mmHg) | 37.2(28.1−48.4) | 33.6(31.4−34.1) | 29.2(21.2−33.2) | 0.3 | − |
| RV dilatation | 0.012 | ||||
|
| 13(62%) | 7(32%) | 21(100%) | ||
|
| 7(33%) | 14(64%) | 0(0%) | ||
|
| 1(4.8%) | 1(4.5%) | 0(0%) | ||
| Acute cor pulmonale | 4(19%) | 11(50%) | 0(0%) | <0.001 | 0.033 |
Three-dimensional echocardiography parameters.
| ARDS related to SARS-CoV-2 (Group 1) | ARDS unrelated to SARS-CoV-2 (Group 2) | Controls (Group 3) | Paired | ||
| Indexed LV end-diastolic volume (mL/m2) | 55 (50–64) | 58 (52–65) | 47 (38–54) | 0.069 | − |
| Indexed LV end-systolic volume (mL/m2) | 23 (19–34)† | 23 (19–28)* | 15 (13–18)*† | 0.002 | 1.00 |
| LV ejection fraction (%) | 56 (46–64)† | 56 (49–64) | 66 (62–71)† | 0.017 | 1.00 |
| Indexed RV end-diastolic volume (mL/m2) | 59 (48–72) | 70 (61–72) | 54 (40–59) | 0.10 | − |
| Indexed RV end-systolic volume (mL/m2) | 23 (16–29) | 35 (31–40)* | 18 (13–22)* | <0.001 | 0.008 |
| RV ejection fraction (%): | 58 (55–62) | 43 (40–57)* | 65 (56–68)* | <0.001 | 0.001 |
| Absolute longitudinal RVEF (%) | 20 (16–23) | 11 (9–18)* | 20 (16–24)* | 0.014 | 0.11 |
| Relative contribution of longitudinal axis (%) | 32 (28–39) | 29 (24–40) | 31 (28–38) | 0.6 | − |
| Absolute anteroposterior RVEF (%) | 29 (25–31)† | 25 (18–32)* | 36 (32–38)*† | <0.001 | 0.57 |
| Relative contribution of anteroposterior axis (%) | 51 (41–55) | 56 (46–63) | 56 (50–64) | 0.076 | − |
| Absolute radial RVEF (%) | 34 (28–38) | 21 (17–28)* | 34 (31–40)* | <0.001 | 0.001 |
| Relative contribution radial axis (%) | 57 (51–62) | 45 (40–53)* | 56 (50–60)* | 0.005 | 0.007 |
FIGURE 2Absolute contribution of RV shortening along each spatial axis to the generation of global ejection fraction in ARDS groups and in the control group. Paired p-values are given when significant and were adjusted with Bonferroni test. The sum of the decomposed volume changes and ejection fractions is not equal to the global values due to the non-additive manner of the motion decomposition. Thus, when analyzing RV shortening along a single axis, the contribution of the given motion direction to global RV volume loss is mathematically overestimated. (A) Violin plot including box plot depicting median value of the absolute longitudinal RVEF in the different groups. (B) Violin plot including boxplot depicting median value of the absolute anteroposterior RVEF in the different groups. (C) Violin plot including boxplot depicting median value of the absolute radial RVEF in the different groups. (D) Stacked bar plot depicting each cumulated median absolute value (indicated in black) of different axes in the ARDS groups and in the control group.
FIGURE 3Relative contribution of RV shortening along each spatial axis to the generation of global ejection fraction in ARDS groups and in the control group. Paired p-values are given when significant and were adjusted with Bonferroni test. The sum of the decomposed volume changes and ejection fractions is not equal to the global values due to the non-additive manner of the motion decomposition. Thus, when analyzing RV shortening along a single axis, the contribution of the given motion direction to global RV volume loss is mathematically overestimated. (A) Violin plot including boxplot depicting median value of the relative longitudinal RVEF in the different groups. (B) Violin plot including boxplot depicting median value of the relative anteroposterior RVEF in the different groups. (C) Violin plot including boxplot depicting median value of the relative radial RVEF in the different groups. (D) Stacked bar plot depicting each cumulated median relative value (indicated in black) of different axes in the ARDS groups and in the control group.
FIGURE 4Representative cases depicting the global motion and the three different mechanical components of the right ventricle (RV) from each ARDS group and from the control group. Color represents each isolated axis of right ventricular end systolic volume (Blue for global, Orange for longitudinal, Yellow for radial and Gray for anteroposterior). Right ventricular mechanics can be appreciated by measuring its shortening along the three spatial axes (green mesh, RV end-diastolic volume; blue surface, end-systolic volume related to global right ventricular ejection fraction). By decomposing RV shortening along the three anatomically relevant axes, theoretical RV end-systolic meshes can be generated in which RV motion is “locked” in two directions and enabled along only one axis (orange surface, longitudinal axis only; yellow surface, radial axis only; gray surface, anteroposterior axis only). In the patient from group 1, global RV ejection fraction was preserved with only a decrease in the anteroposterior shortening when compared to the control. In the patient from group 2, both the global and axial RV ejection fractions were decreased when compared to the control, with a particular impairment of radial shortening.
Intra and Interobserver variability of 3D RV ejection fraction.
| Intraobserver variability | Interobserver variability | |||
| CV, % |
| CV, % |
| |
| Global EF | 5.73 | 0.89 | 5.81 | 0.98 |
| Longitudinal EF | 12.98 | 0.67 | 12.18 | 0.60 |
| Radial EF | 11.55 | 0.91 | 8.82 | 0.83 |
| Anteroposterior EF | 13.33 | 0.73 | 10.57 | 0.87 |
EF, Ejection fraction; CV, Coefficient of variability.